<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>DARU Journal of Pharmaceutical Sciences</JournalTitle><Volume>12</Volume><Issue>1</Issue></Journal><ArticleTitle>"Protective Effects of Some Azo Derivatives of 5-aminosalicylic Acid and Their Pegylated Prodrugs on Acetic Acid-induced Rat Colitis "</ArticleTitle><FirstPage>24</FirstPage><LastPage>30</LastPage><AuthorList><Author><FirstName></FirstName><LastName>Alireza Garjani</LastName></Author><Author><FirstName></FirstName><LastName>Soodabeh Davaran</LastName></Author><Author><FirstName></FirstName><LastName>Mohamadreza Rashidi</LastName></Author><Author><FirstName></FirstName><LastName>Nasrin Malek</LastName></Author></AuthorList><History><PubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>06</Day></PubDate></History><Abstract>The protective and anti-inflammatory effects of azo and azo-linked polymeric prodrugs of 5-aminosalicylic acid (5-ASA) on acetic acid induced colitis in rats were investigated. Three azo prodrugs; 4,4 -dihydroxy-azobenzene-3-carboxilic acid (azo compound I), 4-hydroxy-azobenzene-3,4-dicarboxilic acid (azo compound II), 4,4-dihydroxy-3-formyl-azobenzene-3-carboxylic acid (azo compound III) and their polyethylene glycol (PEG 6000) derivatives were synthesized. Rats were pretreated orally (1 hour prior to induction of colitis) with sulfasalazin (300 mg/kg), azo compounds I, II, III and polyethylene glycol conjugates of azo compounds II and III in doses which had the same amount of 5-ASA as sulfasalazin contains. The colonic damage was examined 24 hours later and characterized by gross microscopic injury and colonic edema. Among prodrugs only azo compound III (215 mg/kg) produced a significant (p</Abstract><web_url>https://daru.tums.ac.ir/index.php/daru/article/view/194</web_url><pdf_url>https://daru.tums.ac.ir/index.php/daru/article/download/194/194</pdf_url></Article></Articles>
